{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:20:38Z","timestamp":1783092038628,"version":"3.54.6"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01521-y","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:42:06Z","timestamp":1783089726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Epidermal Growth Factor Receptor Inhibitors in Locally Advanced and Metastatic Anal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"57","author":[{"given":"Muhammad Shaheer","family":"Mannan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeena","family":"Musheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Basharat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Sial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Waqas","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Al-sadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Kashif","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moazzam","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"issue":"9","key":"1521_CR1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/jnci\/djae096","volume":"116","author":"AA Deshmukh","year":"2024","unstructured":"Deshmukh AA, Lin YY, Damgacioglu H, et al. Recent and projected incidence trends and risk of anal cancer among people with HIV in North America. JNCI J Natl Cancer Inst. 2024;116(9):1450\u20138. https:\/\/doi.org\/10.1093\/jnci\/djae096.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"16suppl","key":"1521_CR2","doi-asserted-by":"publisher","first-page":"e15503","DOI":"10.1200\/JCO.2023.41.16_suppl.e15503","volume":"41","author":"K Jhaveri","year":"2023","unstructured":"Jhaveri K, Modi K, Sarfraz H, et al. 20-year incidence trends of anal squamous cell carcinoma. J Clin Oncol. 2023;41(16suppl):e15503\u201315503. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e15503.","journal-title":"J Clin Oncol"},{"issue":"36","key":"1521_CR3","doi-asserted-by":"publisher","first-page":"13052","DOI":"10.3748\/wjg.v20.i36.13052","volume":"20","author":"MC Osborne","year":"2014","unstructured":"Osborne MC, Maykel J, Johnson EK, Steele SR. Anal squamous cell carcinoma: An evolution in disease and management. World J Gastroenterol WJG. 2014;20(36):13052\u20139. https:\/\/doi.org\/10.3748\/wjg.v20.i36.13052.","journal-title":"World J Gastroenterol WJG"},{"issue":"22","key":"1521_CR4","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1200\/JCO.19.03266","volume":"38","author":"S Rao","year":"2020","unstructured":"Rao S, Sclafani F, Eng C, et al. International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. J Clin Oncol. 2020;38(22):2510\u20138. https:\/\/doi.org\/10.1200\/JCO.19.03266.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1521_CR5","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30445-9.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1521_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrc3309","volume":"12","author":"Y Yarden","year":"2012","unstructured":"Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer. 2012;12(8):553\u201363. https:\/\/doi.org\/10.1038\/nrc3309.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1521_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","volume":"354","author":"JA Bonner","year":"2006","unstructured":"Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2006;354(6):567\u201378. https:\/\/doi.org\/10.1056\/NEJMoa053422.","journal-title":"N Engl J Med"},{"issue":"4suppl","key":"1521_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1200\/jco.2011.29.4_suppl.412","volume":"29","author":"AA Paliga","year":"2011","unstructured":"Paliga AA, Onerheim R, Gologan A, Spatz A, Vuong T. EGFR expression in invasive anal carcinoma. J Clin Oncol. 2011;29(4suppl):412\u2013412. https:\/\/doi.org\/10.1200\/jco.2011.29.4_suppl.412.","journal-title":"J Clin Oncol"},{"issue":"41","key":"1521_CR9","doi-asserted-by":"publisher","first-page":"43594","DOI":"10.18632\/oncotarget.6202","volume":"6","author":"BG Smaglo","year":"2015","unstructured":"Smaglo BG, Tesfaye A, Halfdanarson TR, et al. Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. Oncotarget. 2015;6(41):43594\u2013604. https:\/\/doi.org\/10.18632\/oncotarget.6202.","journal-title":"Oncotarget"},{"issue":"7","key":"1521_CR10","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/modpathol.3800608","volume":"19","author":"G Alvarez","year":"2006","unstructured":"Alvarez G, Perry A, Tan BR, Wang HL. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Pathol Off J U S Can Acad Pathol Inc. 2006;19(7):942\u20139. https:\/\/doi.org\/10.1038\/modpathol.3800608.","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"issue":"6","key":"1521_CR11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","volume":"354","author":"JA Bonner","year":"2006","unstructured":"Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2006;354(6):567\u201378. https:\/\/doi.org\/10.1056\/NEJMoa053422.","journal-title":"N Engl J Med"},{"key":"1521_CR12","unstructured":"In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody1 | clinical cancer research | American Association for cancer research. Accessed May 22. 2026. https:\/\/aacrjournals.org\/clincancerres\/article\/6\/2\/701\/287988\/In-Vivo-Enhancement-of-Tumor-Radioresponse-by-C225"},{"key":"1521_CR13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ Published online March. 2021;29:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ Published online March"},{"key":"1521_CR14","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"1521_CR15","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"1521_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2147\/CLEP.S66677","volume":"6","author":"AV Margulis","year":"2014","unstructured":"Margulis AV, Pladevall M, Riera-Guardia N, et al. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle\u2013Ottawa Scale and the RTI item bank. Clin Epidemiol. 2014;6:359\u201368. https:\/\/doi.org\/10.2147\/CLEP.S66677.","journal-title":"Clin Epidemiol"},{"issue":"3","key":"1521_CR17","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/cam4.2722","volume":"9","author":"J Feliu","year":"2019","unstructured":"Feliu J, Garcia-Carbonero R, Capdevila J, et al. VITAL phase 2 study: Upfront 5\u2010fluorouracil, mitomycin\u2010C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09\u201002). Cancer Med. 2019;9(3):1008\u201316. https:\/\/doi.org\/10.1002\/cam4.2722.","journal-title":"Cancer Med"},{"issue":"7","key":"1521_CR18","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1200\/JCO.2016.69.1667","volume":"35","author":"MK Garg","year":"2017","unstructured":"Garg MK, Zhao F, Sparano JA, et al. Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group\u2013American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol. 2017;35(7):718\u201326. https:\/\/doi.org\/10.1200\/JCO.2016.69.1667.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1521_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000452766","volume":"92","author":"DW Kim","year":"2017","unstructured":"Kim DW, Byer J, Kothari N, Mahipal A, Chang YD, Kim RD. EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience. Oncology. 2017;92(4):190\u20136. https:\/\/doi.org\/10.1159\/000452766.","journal-title":"Oncology"},{"issue":"18","key":"1521_CR20","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1016\/j.ejca.2015.08.029","volume":"51","author":"O Leon","year":"2015","unstructured":"Leon O, Guren MG, Radu C, Gunnlaugsson A, Johnsson A. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. Eur J Cancer. 2015;51(18):2740\u20136. https:\/\/doi.org\/10.1016\/j.ejca.2015.08.029.","journal-title":"Eur J Cancer"},{"issue":"11","key":"1521_CR21","doi-asserted-by":"publisher","first-page":"e002996","DOI":"10.1136\/jitc-2021-002996","volume":"9","author":"S Lonardi","year":"2021","unstructured":"Lonardi S, Prete AA, Morano F, et al. Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. J Immunother Cancer. 2021;9(11):e002996. https:\/\/doi.org\/10.1136\/jitc-2021-002996.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"1521_CR22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000259615","volume":"77","author":"N Lukan","year":"2009","unstructured":"Lukan N, Str\u00f6bel P, Willer A, et al. Cetuximab-Based Treatment of Metastatic Anal Cancer: Correlation of Response with KRAS Mutational Status. Oncology. 2009;77(5):293\u20139. https:\/\/doi.org\/10.1159\/000259615.","journal-title":"Oncology"},{"issue":"10","key":"1521_CR23","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/14737140.2020.1810573","volume":"20","author":"JE Rogers","year":"2020","unstructured":"Rogers JE, J\u00e1come AAA, Ohinata A, et al. Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma. Expert Rev Anticancer Ther. 2020;20(10):901\u20138. https:\/\/doi.org\/10.1080\/14737140.2020.1810573.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1521_CR24","doi-asserted-by":"publisher","unstructured":"Rogers JE, Sirisaengtaksin A, Leung M, et al. Hepatic metastasectomy in squamous cell carcinoma of the anal canal: a case series of a curative approach. Cancers. 2023;15(15). https:\/\/doi.org\/10.3390\/cancers15153890.","DOI":"10.3390\/cancers15153890"},{"issue":"7","key":"1521_CR25","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/JCO.2016.69.1642","volume":"35","author":"JA Sparano","year":"2017","unstructured":"Sparano JA, Lee JY, Palefsky J, et al. Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial. J Clin Oncol. 2017;35(7):727\u201333. https:\/\/doi.org\/10.1200\/JCO.2016.69.1642.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1521_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.dld.2022.08.026","volume":"55","author":"M Valery","year":"2023","unstructured":"Valery M, Cervantes B, Smolenschi C, et al. Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma. Dig Liver Dis. 2023;55(3):407\u201311. https:\/\/doi.org\/10.1016\/j.dld.2022.08.026.","journal-title":"Dig Liver Dis"},{"key":"1521_CR27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.radonc.2019.05.018","volume":"140","author":"V Vendrely","year":"2019","unstructured":"Vendrely V, Lemanski C, Gnep K, et al. Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904). Radiother Oncol. 2019;140:84\u20139. https:\/\/doi.org\/10.1016\/j.radonc.2019.05.018.","journal-title":"Radiother Oncol"},{"key":"1521_CR28","doi-asserted-by":"publisher","first-page":"109742","DOI":"10.1016\/j.radonc.2023.109742","volume":"186","author":"V Vendrely","year":"2023","unstructured":"Vendrely V, Ronchin P, Minsat M, et al. Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial. Radiother Oncol. 2023;186:109742. https:\/\/doi.org\/10.1016\/j.radonc.2023.109742.","journal-title":"Radiother Oncol"},{"issue":"11","key":"1521_CR29","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N Engl J Med. 2008;359(11):1116\u201327. https:\/\/doi.org\/10.1056\/NEJMoa0802656.","journal-title":"N Engl J Med"},{"issue":"11","key":"1521_CR30","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"JY Douillard","year":"2013","unstructured":"Douillard JY, Oliner KS, Siena S, et al. Panitumumab\u2013FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. N Engl J Med. 2013;369(11):1023\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1305275.","journal-title":"N Engl J Med"},{"key":"1521_CR31","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.3816\/CCC.2005.s.003","volume":"5","author":"D Vallb\u00f6hmer","year":"2005","unstructured":"Vallb\u00f6hmer D, Lenz HJ. Epidermal Growth Factor Receptor as a Target for Chemotherapy. Clin Colorectal Cancer. 2005;5:S19\u201327. https:\/\/doi.org\/10.3816\/CCC.2005.s.003.","journal-title":"Clin Colorectal Cancer"},{"issue":"8","key":"1521_CR32","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1016\/S1470-2045(14)70291-8","volume":"15","author":"TJ Price","year":"2014","unstructured":"Price TJ, Peeters M, Ruff P, Murugappan S, Sidhu R. ASPECCT: panitumumab versus cetuximab for colorectal cancer \u2013 Authors\u2019 reply. Lancet Oncol. 2014;15(8):e303. https:\/\/doi.org\/10.1016\/S1470-2045(14)70291-8.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1521_CR33","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","volume":"14","author":"RD James","year":"2013","unstructured":"James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 \u00d7 2 factorial trial. Lancet Oncol. 2013;14(6):516\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(13)70086-X.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1521_CR34","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1038\/s41467-024-47433-y","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Pattarayan D, Huang H, et al. Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer. Nat Commun. 2024;15(1):3178. https:\/\/doi.org\/10.1038\/s41467-024-47433-y.","journal-title":"Nat Commun"},{"issue":"6","key":"1521_CR35","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/JTO.0000000000000500","volume":"10","author":"N Chen","year":"2015","unstructured":"Chen N, Fang W, Zhan J, et al. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation. J Thorac Oncol. 2015;10(6):910\u201323. https:\/\/doi.org\/10.1097\/JTO.0000000000000500.","journal-title":"J Thorac Oncol"},{"key":"1521_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2018.01.005","volume":"418","author":"X Li","year":"2018","unstructured":"Li X, Lian Z, Wang S, Xing L, Yu J. Interactions between EGFR and PD-1\/PD-L1 pathway: Implications for treatment of NSCLC. Cancer Lett. 2018;418:1\u20139. https:\/\/doi.org\/10.1016\/j.canlet.2018.01.005.","journal-title":"Cancer Lett"},{"issue":"9","key":"1521_CR37","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.annonc.2021.06.015","volume":"32","author":"S Rao","year":"2021","unstructured":"Rao S, Guren MG, Khan K, et al. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2021;32(9):1087\u2013100. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.015.","journal-title":"Ann Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01521-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01521-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01521-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:42:13Z","timestamp":1783089733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01521-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1521"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01521-y","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Institutional Review Board approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval\/IRB"}},{"value":"Not applicable. The study used previously published data and did not involve direct human participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable. This study is a systematic review and meta-analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}}],"article-number":"146"}}